ent SafetyNet system-monitored
patients. Researchers concluded that, "the system supported the early
identification of patients with sedation or analgesia-induced respiratory
depression," as well as the "early recognition of other patterns of
deterioration, including: poor heart rate control, acute bradycardia
needing atropine, new onset A-fib, unrecognized obstructive patterns of
respiration like sleep apnea, and pulmonary complications such as fat
emboli syndrome, pulmonary embolus and edema." In addition, researchers
also noted that the system rated high for up-time at 99.9995% and nursing
satisfaction, as identified by 'desire to keep vs. remove the system', at
5.5 on a 6 point scale.
Do Pulse CO-Oximeter Measures of SpMet and SpO2 Correlate with Blood
Gas CO-Oximetry in Neonates?(2), a clinical study led by Dr. Mitchell R.
Goldstein at Loma Linda Children's Hospital in Loma Linda, California,
evaluated whether methemoglobin saturation (SpMet(TM)) could be
successfully measured in neonates without compromise in oxygen saturation
(SpO2) accuracy. Researchers compared noninvasive SpMet and SpO2
measurements obtained from neonates using the Masimo Radical-7 Pulse
CO-Oximeter and Rainbow R25-L disposable sensor with MetHb and SaO2
measurements obtained from blood gas analysis using a laboratory
CO-oximeter and found that the accuracy of SpMet (with a Bias of 0.17,
Standard Deviation of 0.92, and Average Root Mean Square of 0.93) and SpO2
(with a Bias of 1.4, Standard Deviation of 2.46, and Average Root Mean
Square of 2.86) was maintained and correlated with blood gas measurements.
Researchers concluded that Masimo's multi-wavelength Pulse CO-Oximeter "can
simultaneously measure SpMet and SpO2 in neonates," and that "continuous
monitoring of MetHb allows better assessment of toxicity and helps identify
the need for ongoing treatment."
Ability of Pleth Variability Index to Non Invasively Predict the
Hemodynamic Effects of PEEP(3) -- led by Dr. Olivier De
'/>"/>
SOURCE Masimo Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients2.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound3.
Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States4.
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma5.
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials6.
Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio7.
ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials8.
Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs9.
Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia10.
YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer11.
New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome